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RBST, IT DOES A BODY GOOD?: RBST
LABELING AND THE FEDERAL DENIAL OF
CONSUMERS' RIGHT TO KNOW
Christina Cusimano*
I. INTRODUCTION
For more than a decade, a cloud of skepticism has loomed
over the Food and Drug Administration's (FDA) approval of
Recombinant Bovine Growth Hormone' (rBGH) for use on
dairy cattle. The Monsanto Corporation is the sole producer of
rBGH.2 Studies, wholly sponsored by Monsanto, were the
basis of the FDA's decision to approve the commercial use of
rBGH, despite mounting evidence of serious adverse effects in
humans.3 The FDA found it did not have authority under the
Food, Drug, and Cosmetic Act (FDCA) to require labeling of
milk derived from treated cows.4 However, the FDA did
* Technical Editor, Santa Clara Law Review, Volume 48; J.D. Candidate 2008,
Santa Clara University School of Law; B.A. Business Economics and B.A.
Global Studies, University of California at Santa Barbara. I would like to thank
my family, my extended family at the Giant Peach, and my friends that have
become family. This is dedicated to the memory of my red sweatshirt.
1. Recombinant Bovine Somatotropin (rBST) and Recombinant Bovine
Growth hormone (rBGH) refer to the same hormone and will be used
interchangeably throughout this comment.
2. Rachel Melcer, Got Milk Without Hormones? It's Headed Toward St.
Louis Shelves, ST. LOUIS POST-DISPATCH, Nov. 3, 2006, available at
http://www.organicconsumers.org/articles/article_3289.cfm; Serra M. Wayne,
Comment, Ensuring the Safety of Genotech Drugs through Implied Warranty
Theory, 23 AM. J.L. & MED. 363, 369 (1997).
3. SAMUEL S. EPSTEIN, WHAT'S IN YOUR MILK?: AN EXPOSE OF INDUSTRY
AND GOVERNMENT COVER-UP ON THE DANGERS OF THE GENETICALLY
ENGINEERED (RBGH) MILK YOU'RE DRINKING 5 (Trafford Publishing 2006).
4. Interim Guidance on the Voluntary Labeling of Milk and Milk Products
From Cows That Have Not Been Treated With Recombinant Bovine
Somatotropin, 59 Fed. Reg. 6279, 6280 (Feb. 10, 1994) [hereinafter Interim
Guidance].
1095
SANTA CLARA LAW REVIEW
release suggested guidelines for states to follow when
enacting and interpreting statutes related to labeling of milk
and milk related products.5
Currently, states maintain their traditional role as
regulators of milk within their jurisdiction,6 but with some
Monsanto-imposed limitations.7 State attempts to implement
mandatory labeling schemes have come under constitutional
attack and have been largely unsuccessful.8 State voluntary
labeling laws have been upheld in the courts, although
several state-approved labels have been modified after
aggressive attacks on their legality by Monsanto. 9 The FDA
suggested that states permitting farmers to voluntarily label
milk as "rBST-free" also disclose that the FDA concluded
there are no detectable differences between milk from treated
and untreated cows.1° Monsanto has successfully lobbied for
the mandatory inclusion of this tag line.1
The current labeling structure of milk and milk products
derived from rBST treated cows is inadequate and
misleading. The FDA has ignored evidence of health risks
associated with the use of this synthetic growth hormone 2
and consumers are unknowingly forced to do the same. For a
decade, mandatory labeling has been prohibited because
Monsanto's scientific reports, which did not include long-term
testing, 3 indicated no substantial difference between milk
5. See id. at 6280.
6. See id.
7. See infra Part II.D.3. Monsanto sent thousands of letters threatening to
sue manufacturers if they used statements such as "'Our Farmers' Pledge: No
Artificial Growth Hormones" on labels. Jennifer R. Thornley, Comment, Got
"Hormone Free" Milk?: Your State May Have Enough Interest to Let You Know,
76 IND. L.J. 785, 799 (2001); Press Release, Monsanto Co., Monsanto Statement
Regarding Oakhurst Dairy Inc. Filing, available at
http://www.monsantodairy.com/updates/OakhurstDairyInc.Filing.html (last
visited Jan. 11, 2007).
8. See H.B. 7444, 2003-2004 Leg. Sess. (2003-2004); Int'l Dairy Foods Ass'n
v. Amestoy, 92 F.3d 67 (2d Cir. 1996).
9. See Int'l Dairy, 92 F.3d 67; Edward D. Murphy, Oakhurst to Alter Its
Label In Its Settlement With Monsanto, The Portland-Based Dairy Is Allowed To
Keep Its No Growth Hormone Pledge, But Must Add Footnote, PORTLAND PRESS
HERALD, Dec. 25, 2003, at 1A.
10. See Interim Guidance, supra note 4, at 6280.
11. See infra Part IV.B.
12. Letter from Fairview Indus. to the Editor, Fairview Industries: Sales of
Milk Hormones rBGH Must be Suspended: Diabetes Risk; A Comment on Forbes
'8/21/00 Stepping in It,' PR NEWSWIRE, Oct. 27, 2000.
13. See Stauber v. Shalala, 895 F. Supp. 1178, 1192 (W.D. Wis. 1995).
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from treated and untreated cows.14 Like many FDA approved
drugs, 5 studies show serious risks associated with the use of
rBST.16 Short of recalling the drug altogether, the Federal
Government should amend the FDCA17 to mandate labeling
of rBST milk, to protect the health and safety of our nation.
This comment challenges the federal government's
refusal to require labels on products that alert the consumer
that cows treated with synthetic bovine growth hormones are
the source of the product. Part II of this comment begins with
an explanation of rBST and how rBST affects humans that
consume milk from cows treated with rBST. A look into the
FDA's approval of rBST and the role that the sole
manufacturer of rBST played in its approval is also discussed.
Part II concludes with a look at the current Federal law, and
the challenges brought to courts by farmers, consumers, and
the manufacturer of rBST.
Part III identifies the problem as the federal
government's refusal to find that is has authority under the
FDCA and the United States Constitution, to mandate
farmers' use of truthful labels on all milk from cows treated
with rBST. Lastly, in Part V this comment discusses three
possible alternatives to permit manufacturers and producers
to inform consumers of the risks associated with rBST.
II. BACKGROUND
In order to understand the gravity of the rBST-labeling
dilemma, four foundational elements must first be explored.
First, the development of rBST, what it is, and why dairy
farmer's use it. Next, the effects that rBST has on both
treated cows and humans that consume products originating
from cows treated with rBST. Third, information about
corporate giant Monsanto and its ties to the FDA as well as
other powerful politicians. Finally, the FDA's purported
reasons for its decision not to require labels on those products
14. Id. at 1186.
15. See Gary W. Lawson, Impact of User Fees on Changes within the Food
and Drug Administration (May 2005) (unpublished D.P.A. dissertation,
University of La Verne), http//www.fdastudy.com/Thesis.htm (last visited Mar.
24, 2008) [hereinafter Dissertation] ("Overall, fifty-one percent of approved
drugs have serious adverse effects not detected prior to approval.").
16. See infra Part II.B.1-2.
17. 21 U.S.C. §§ 301-394 (2006).
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originating from cows treated with rBST and consumer's
reaction to the FDA's choice.
A. What is rBGH?
Bovine growth hormone (BGH), also known as bovine
somatotropin (BST), is a naturally occurring protein hormone
produced in the pituitary gland that supports the growth and
lactation of dairy cows. 8 In the 1980's, through recombinant
DNA biotechnology, scientists developed rBST, a synthetic
version of the naturally occurring BST hormone. 19 Simply
put, the BST gene is first isolated, and then inserted into the
genomes of bacteria, which rapidly reproduce the hormone.2 °
The hormones are then harvested 21 and administered
intravenously to cows. 22 Similar to insulin, rBST is a protein
hormone, meaning it has no effect if taken orally; therefore, it
must be injected directly into the cow's bloodstream.23 Once
injected, rBST is carried to the cow's liver where it stimulates
production of Insulin-like Growth Factor (IGF-1), 24 which
then stimulates milk production.25
In November 1993, the FDA approved the commercial
sale and distribution of rBGH to begin in 1994.26 Although
four major United States corporations were developing the
artificial hormone throughout the 1980s,27  Monsanto's
product was the only version approved. 28  To this day,
Monsanto maintains a monopoly as the sole producer of
18. Use of Bovine Somatotropin (BST) in the United States: Its Potential
Effects, A Study Conducted by the Executive Branch of the Federal
Government, Jan. 1994, available at
http://www.biotech.wisc.edu/Outreach/ombreport.html [hereinafter Executive
Branch Study].
19. Id.
20. Stauber v. Shalala, 895 F. Supp. 1178, 1183 (W.D. Wis. 1995).
21. M. Leann Brown, Learning and Food Security in the European Union, in
ORGANIZATIONAL LEARNING IN THE GLOBAL CONTEXT 21 n.2 (M. Leann Brown,
Michael Kenney & Michael J. Zarkin eds., 2006).
22. See David Barbano, bST Fact Sheet, Cornell University (1995), available
at http://www.cfsan.fda.gov/-ear/CORBST.html (last visited Mar. 24, 2007).
23. Id.
24. Id.
25. Id.
26. Int'l Dairy Foods Ass'n v. Amestoy, 92 F.3d 67, 67 (2d Cir. 1996).
27. Emily Marden, Comment, In Search of Justice, 46 DRAKE L. REV. 617,
621 (1998). The four corporations vying for a marketable version of rBST were
Monsanto, American Cyanamid, Upjohn and Eli Lilly. Id.
28. Id.
1098 [Vo1:48
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rBGH.29
When dairy farmers supplement the amount of naturally
occurring BST with Monsanto's rBST, distributed under the
name "Posilac," the result is a ten to twenty percent increase
in milk production. 0 rBGH is administered to approximately
one-third of dairy herds in the United States. 1 Dean Foods,
the largest milk producer in the United States, reported that
only ten percent of its milk processing plants offers milk from
untreated cows, 32 although it is gradually moving in the
direction of being hormone free.3 While Monsanto and the
FDA continue to deny any adverse affects associated with use
of rBST,34 consumers and researchers persist in challenging
the truth of rBST proponents' claims. 5
B. Effects of rBST
There are over twenty toxic effects to cows caused by the
use of rBST 6 Two, mastitis and increased levels of IGF-1,
29. Rachel Melcer, Looking For Milk Without Hormones?, ST. LOUIS POST-
DISPATCH, Nov. 3, 2006, at B1.
30. Executive Branch Study, supra note 18.
31. Andrew Pollack, Which Cows do You Trust?, N.Y. TIMES, Oct. 7, 2006, at
C1.
32. Id.
33. Id.
34. See Monsanto, Focus on Posilac,
http://www.monsanto.com/posilacddefault.asp. Monsanto's website claims rBST
"safely enhances milk production .... Milk from cows receiving supplemental
bST [rBST] is unchanged and just as wholesome and nutritious as always ...
levels of bST in milk remain the same." Id. The FDA claimed it "found no
pertinent information" on risks associated with rBST. EPSTEIN, supra note 3, at
214.
Meanwhile, farmers only seem to care about their bottomline. Monsanto, See
What Farmers are Saying About Posilac@,
http://www.monsantodairy.com/farmer/index.html (providing examples of
farmers' thoughts on Posilac, such as "If Posilac wasn't profitable, we wouldn't
be using it;" "I use Posilac because it makes me money;" and "We've kept cows
in our herd making money that would have been sold without Posilac.").
35. EPSTEIN, supra note 3, at 213-14 ("A scientific publication by Dr. [Dale]
Bauman [Professor of Animal Sciences at Cornell University] falsely claimed
that 'no adverse health effects were observed (in a herd of rBST injected cows).
. . animals were in good health throughout the study.' In fact, Bauman
suppressed evidence of a high incidence of mastitis in the treated herd.").
36. See Stauber v. Shalala, 895 F. Supp. 1178, 1183 (W.D. Wis. 1995)
("Posilac increases the risks of reduced pregnancy rates, ovarian cysts and
uterine disorders, decreased lengths of gestation periods, lower birth weight of
calves, retained placentas and twinning rates, may cause increased bovine body
temperatures, indigestion, bloating, diarrhea, enlarged hocks, enlarged lesions,
and injection site swellings."); see also EPSTEIN, supra note 3, at 185 (noting the
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have a direct effect on human health and safety.37
1. Mastitis and Antibiotics
The FDA concluded that clinical and subclinical mastitis,
a bacterial infection of the udder, "increased moderately" in
cows treated with rBST .3  The United States Government
Accountability Office (GAO) 39 voiced concerns about the
increased incidence of mastitis.4 °Specifically, the GAO
reported that rBST results in higher rates of mastitis in
cows. 41  Mastitis is treated with antibiotics, and the GAO
voiced concern that increased infections in cows would lead to
increased use of antibiotics by farmers, which in turn would
increase the amount of drug residue in milk.42 Furthermore, a
study conducted by veterinarians showed Posilac caused
mastitis in up to twenty-five percent of cases.43 Other studies
show a seventy-nine percent increase.44 However, the FDA
considered the increased risk negligible, 45 and approved the
package insert for Posilac lists over twenty toxic effects).
37. See infra Part II.B.1-2.
38. Stauber, 895 F. Supp. at 1183.
39. The Government Accountability Office (GAO) is frequently referred to as
"the investigative arm of Congress" and "the congressional watchdog." General
Accounting Office, Welcome to GAO, http'//www.gao.gov/ (last visited Feb. 15,
2008) (describing the functions of the GAO: "GAO supports the Congress in
meeting its constitutional responsibilities and helps improve the performance
and ensure the accountability of the federal government for the benefit of the
American people. GAO's work includes . . . insight into ways to make the
government more efficient, effective, ethical and equitable .... GAO's reports,
testimonies, legal decisions and opinions make a difference for Congress and the
Nation.").
40. Executive Branch Study, supra note 18, at 7.
41. U.S. GENERAL ACCOUNTING OFFICE, RECOMBINANT BOVINE GROWTH
HORMONE, FDA APPROVAL SHOULD BE WITHHELD UNTIL THE MASTITIS ISSUE IS
RESOLVED, GAO/PEMD-92-26: B-248450 (1992).
42. Id.; see also Letter from Robert P. Murphy to The Honorable George E.
Brown, Jr., Chairman, Comm. on Sci., Space and Tech. H.R., The Honorable
David Obey, H.R., and The Honorable Bernard Sanders, H.R. (Oct. 19, 1994),
available at httpJ/archive.gao.gov/auditpapr2pdf4l152883.pdf [hereinafter
Letter to Congress].
43. Ed Maixner, U.S., Canada Divided on Safety of BST to Cows,
FEEDSTUFFS, Feb. 1, 1999, at 1.
44. Rose Marie Williams, Bovine Growth Hormone Cover-Up (Health Risks
and Environmental Issues), TOWNSEND LETTER FOR DOCTORS AND PATIENTS,
Nov. 1, 2006, available at WLNR 19904469 [hereinafter TOWNSEND].
45. See Stauber v. Shalala, 895 F. Supp. 1178, 1183 (W.D. Wis. 1995) (The
"risk [of mastitis from using Posilac] is less than the risk of mastitis posed by
seasonal change.").
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drug.46
Once cows are afflicted with mastitis, farmers give the
cows antibiotics to cure the disease.47 Mastitis may lead to
high levels of antibiotic residue in milk, as well as, an
increase in pus content.48 Despite assertions from the FDA
and Monsanto that the milk is safe, 49 both consumers and
members of the scientific community have voiced concerns
about adverse allergic reactions to the antibiotics in humans50
as well as the decreased potency of antibiotics, such as
penicillin, due to an acquired resistance from exposure.51
Currently, there are regulations in place that require
inspection of milk for antibiotic residue. 52 These regulations
instruct farmers to discard milk that contains residue in
excess of standard levels.53 According to the FDA and
Monsanto, these inspection practices protect consumers,54
which they claim make mastitis a "manageable" problem.55
However, while farmers use over fifty different drugs to cure
the disease, these tests only assess levels of the four
antibiotics most commonly used to treat mastitis.56
46. Id. at 1184 ("The FDA has never applied a zero risk standard when
assessing the safety of new animal drugs."). In 1986, the House Committee on
Government Operations concluded that the "FDA has consistently disregarded
its responsibility, . . . has repeatedly put what it perceives are interests of
veterinarians and the livestock industry ahead of its legal obligations to protect
consumers ... jeopardizing the health and safety consumers of meat, milk, and
poultry." SAMUEL S. EPSTEIN, CANCER-GATE: HOW TO WIN THE LOSING CANCER
WAR 190 (2005) (citing H. COMM. GOV. OPERATIONS, HUMAN FOOD SAFETY AND
REGULATION OF ANIMAL DRUGS (1986)).
47. Letter to Congress, supra note 42, at 13-14; Marden, supra note 27, at
624.
48. Marden, supra note 27, at 624.
49. See Interim Guidance, supra note 4; Press Release, supra note 7; see also
supra text accompanying note 32.
50. See EPSTEIN, supra note 3; see also David Phillips, Will rBST RIP?,
DIARY FOODS, Oct. 1, 2006 at 8; Stauber, 895 F. Supp. at 1192.
51. Toronto Food Policy Council, The Canadian Regulatory Process For
Evaluating Recombinant Bovine Growth Hormone in the Dairy Industry: A
Critical Review 60 (Discussion Paper No. 12, 2000) [hereinafter Toronto]; Letter
to Congress, supra note 42, at 14.
52. Stauber v. Shalala, 895 F. Supp. 1178, 1184 (W.D. Wis. 1995)
(discussing the Grade A Pasteurized Milk Ordinance established by the FDA,
the Public Health Service, state and local regulatory agencies and members of
the milk industry).
53. Id.
54. See id. at 1184-85.
55. Id. at 1184.
56. Id.
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Contamination by these other drugs goes undetected
according to the GAO.
Regardless of whether or not Monsanto acknowledges the
evidence that shows a correlation between rBST and
increased incidents of mastitis, or the insufficient safeguards
to protect consumers to antibiotic exposure, a great number of
citizens recognize, and are concerned that the first toxic
effect, mastitis, has a direct effect on human health and
safety.58
2. Increased Levels of IGF-1
The second serious effect is the increased level of Insulin-
like Growth Factor-1 (IGF-1) discovered in treated cows. 9
Monsanto has failed to conduct any long term studies on the
effects of increased levels of IGF-1 on human health.60 Still,
Monsanto justifies its claim that the increased levels of IGF-1
are safe for human consumption because the amount of IGF-1
present in treated cows is less than the amount found in
human breast milk.6' Although the factual assertion by
Monsanto is true, it is irrelevant to the issue of safety.62 The
typical child, whose development is assisted by IGF-1, 63
consumes mother's milk for less than a year, while human
consumption of cow's milk may last a lifetime. 64 Eli Lilly65
admitted that the blood of cows treated with rBST contains
levels of IGF-1 ten times greater than that of untreated
57. Id. ("The General Accounting Office has concluded that there is
currently no means of assessing the degree to which current milk supplies are
contaminated by these other drugs .... To date there have been no long term
studies of the impact on human health of increased antibiotics in milk.").
58. See Stauber, 895 F. Supp. at 1185; Int'l Dairy Foods Ass'n v. Amestoy,
92 F.3d 67, 69 (2d Cir. 1996).
59. Stauber, 895 F. Supp. at 1185 ("IGF-lis protein hormone whose
production is regulated at least in part by somatotrophin. It has the same
biochemical composition in humans and cows and is present in all milk, human
saliva and human digestive juices. RbST increases the amount of IGF-1 in
milk.").
60. Id. at 1185.
61. Toronto, supra note 51, at 46.
62. Id. at 47.
63. Id. IGF-1 assists in the development of a newborn's gut; assistance that
is not generally needed past infancy. Id.
64. Id.
65. Eli Lilly is a global pharmaceutical company and one of the world's
largest corporations. See Eli Lilly, http://www.lilly.com/. Eli Lilly employs
42,000 people worldwide and markets its medicines in 143 countries. See Eli
Lilly, About, httpJ/www.lilly.com/about/index.html (last visited Feb. 15, 2008).
[Vo1:481102
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cows. 66 Furthermore, researchers observed increases of IGF-1
up to 700 percent in cow's blood during an injection period.6 7
Elevated levels of IGF-1 in humans could possibly induce
premature growth in infants. 6  Further, there is a positive
correlation between levels of IGF-1 and both breast and
gastrointestinal cancer. One study analyzing the
relationship between IGF-1 concentration and breast cancer
risk found no relation between IGF-1 and breast cancer risk
among postmenopausal women. ° However, the study did
find that pre-menopausal women with higher levels of IGF-1
are up to seven times more likely to develop breast cancer
than women with lower levels.7'
To assess human toxicity, Monsanto conducted a two
week study in which rats were given IGF-1.7 ' The tests
showed no negative health impact on the esophagus, stomach,
or intestines,73 but the rats' body and liver weights along with
bone length significantly increased.74 A ninety-day study
66. Samuel S. Epstein, Despite Industry Propaganda Monsanto's Bovine
Growth Hormone Still Threatens Public Health (Feb. 3, 2006),
http://www.organicconsumers.org/rBGH/milkismilk20405.cfm; see also
Statement by the Cancer Prevention Coalition on IGF-1 and Breast and Colon
Cancer (Jan. 23, 1996),
http://www.preventcancer.com/consumers/general/bioengineered.htm. Eli
Lilly's research division, Lilly Research Laboratories:
is responsible for the discovery, development and clinical evaluation of
[its] . . . products . . . . Lilly Research Laboratories comprises
approximately 7,900 people from a wide variety of scientific disciplines
... [Eli Lilly is] among the industry's leaders in . . . research and
development.., investing substantial sums for talent and capabilities
in R&D.
Eli Lilly, R&D, Lilly Research Laboratories,
http://www.lilly.com/researchlindex.html (last visited Feb. 15, 2008).
67. Toronto, supra note 51, at 47; see also EPSTEIN, supra note 3, at 149-50.
68. EPSTEIN, supra note 3, at 78; see also J.R. Harris et al., Breast Cancer, 7
N. ENGL. J. MED. 473, 473-80 (1992); V. Pappa et al., Insulin-like Growth
Factor-1 Receptors Are Overexpressed and Predict a Low Risk in Human Breast
Cancer, 53 CANCER RES. 3736, 3736-40 (1993).
69. EPSTEIN, supra note 3, at 78; see also J.R. Harris et al., supra note 68,
at 473-80; V. Pappa et al., supra note 68, at 3736-40.
70. Susan E. Hankinson et al., Circulating Concentrations of Insulin-like
Growth Factor I and Risk of Breast Cancer, 351 THE LANCET 1393, 1393-96
(1998).
71. Id.
72. Stauber v. Shalala, 895 F. Supp. 1178, 1185 (W.D. Wis. 1995).
73. Id.
74. Judith C. Juskevich & C. Greg Guyer, Bovine Growth Hormone: Human
Food Safety Evaluation, 249 SCI. 875, 880-81 (1990); see also Epstein, Despite
Industry Propaganda, supra note 66.
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conducted by the Health Protection Branch (HPB) of Health
Canada revealed significant absorption of rBST and toxicity
to the rats.75
Prior to the study conducted by HPB, Dr. Richard
Burroughs, the lead veterinary scientist for the FDA's Center
for Veterinary Medicine (CVM), recommended further
assessment of rBST out of serious concern for the veterinary
toxicology.76 Not long after, in 1989, the CVM fired Dr.
Burroughs for alleged incompetence." Dr. Guest, the director
of CVM stated Burroughs was "slowing down his approval
process.""8  Similarly, the FDA's Director of Toxicology,
Alexander Apostolou, spoke out against the FDA's failure to
adequately evaluate the human food safety of veterinary
drugs such as rBST, afterwhich, the FDA pressured him to
resign.79
Despite several independent scientists and congressmen
urging further testing to discover the long-term effects of
increased levels of IGF-1 on humans,80 Monsanto has not
conducted any such studies.8 ' The longest toxicology study
acknowledged by the FDA was a ninety-day study performed
on adult rats submitted by Monsanto. 2
Canada, New Zealand, Europe, and Japan have banned
the use of rBST.13 The European Union's current ban is an
extension of a moratorium placed on rBST, when the FDA
first approved it in 1993, for socioeconomic reasons, which
75. U.S. Food & Drug Administration, Center for Veterinary Medicine,
Update on Human Food Safety of BST, (Feb. 5, 1999),
http://www.fda.gov/cvm/CVM Updates/BSTSAFUP.html.
76. EPSTEIN, supra note 3, at 78.
77. Id. at 137.
78. Id.
79. TOWNSEND, supra note 44, at 1.
80. See Letter to Congress, supra note 42.
81. Stauber v. Shalala, 895 F. Supp. 1178, 1185 (W.D. Wis. 1995). A
member of the United Kingdom Food Ethics Council stated that due to the lack
of conclusive studies, any approval of rBST shows "a total disregard for the
precautionary principle." Kelly Morris, Bovine Somatotropin - Who's Crying
Over Spilt Milk?, 353 THE LANCET 306, 306 (1999). "Further studies will be
required to determine whether the ingestion of higher than normal
concentrations of bovine insulin-like growth factor is safe for children,
adolescents and adults." American Medical Ass'n, Council on Scientific Affairs,
Biotechnology and the American Agriculture Industry, 265 JAMA 1429 (1991).
82. Morris, supra note 81, at 306.
83. EPSTEIN, supra note 3, at 48.
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was to last until 1999.4 Canada's ban came after a 1998
report by HPB found rBST to be unsafe for cows.8 5
C. Monsanto Corporation
Monsanto is a major agricultural corporation, reporting a
gross profit of 4.2 billion dollars in 2007.6 In addition to
Posilac, Monsanto's production endeavors include: (1) Agent
Orange, a toxic chemical known to cause cancer, neurological
disorders, birth defects, and death, and is now banned; 7 (2)
PCBs, industrial coolants, now known global pollutants, 8
which have also been banned but only after forty years of
damage was done;89 (3) a plethora of genetically modified
crops, including cotton and soy,90 equipped with the patented
"terminator gene" that prevents replanting of seeds from
harvested crops;91 and (4) Roundup herbicide, composed of the
highly toxic chemical glyphosate, to which only Monsanto's
genetically modified crops are tolerant.92
It is no secret that large corporations are dominating
forces in today's world. Lobbyist efforts, campaign
contributions, and the fluidity with which corporate directors
and officers move in and out of government positions enable a
system of corporate influence. Monsanto's tactics in the
approval of rBST are highly suspect, as demonstrated
through its ties to government agencies and officials.
84. Morris, supra note 81, at 306.
85. Toronto, supra note 51, at 49.
86. MONSANTO Co., 2007 ANNuAL REPORT 52, available at
http://www.monsanto.com/pdf/pubs/2007/2007AnnualReport.pdf.
87. Meryl Nass, Monsanto's Agent Orange: The Persistent Ghost from the
Vietnam War,
http://www.organicconsumers.org/monsanto/agentorange032102.cfm (last
visited Jan. 2, 2007).
88. Michael Grunwald, Monsanto Hid PCB Pollution for Decades, WASH.
POST, Jan. 1, 2002, at Al.
89. Id. ("Monsanto routinely discharged toxic waste into a west Anniston
creek and dumped millions of pounds of PCBs into oozing open pit landfills.").
90. Monsanto manufactures terminator seeds for soy, cotton, tomatoes,
alfalfa and wheat. Monsanto, Our Products,
http://www.monsanto.com/products/default.asp (last visited Mar. 24, 2008).
91. Editorial, Some of the President's Monsanto Men, IDAHO OBSERVER, Feb.
2001, available at http://proliberty.com/observer/20010208.htm.
92. Press Release, Inst. of Sci. in Soc'y, Monsanto Steadily Poisoning the
World with Roundup Herbicide & GMO Crops (July 3, 2005), available at
http://www.organicconsumers.org/monsanto/poisoning03O85.cfm.
2008] 1105
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1. Former Monsanto Employees Work for the FDA
The FDA's Office of Chief Counsel hired Michael Taylor
in 1976 where he remained as a legal advisor until 1980."'
Mr. Taylor left the FDA in 1981 to work for the law firm of
King & Spalding.94 As the supervisor of the food and drug
group, Mr. Taylor acted as chief counsel for Monsanto.95 In
1991, Mr. Taylor returned to the FDA, this time as
Commissioner for Policy.96 Mr. Taylor was still Commissioner
when the FDA approved Posilac.9 v Although Mr. Taylor
attempted to avoid involvement in Monsanto's application,9"
he later wrote the FDA regulations banning the labeling of
milk.99
Dr. Margaret Miller served as a chemical laboratory
supervisor for Monsanto from 1985 through 1989.10 Dr.
Miller was responsible for validating tests that measured
levels of IGF-1 and bST in cows.' 0 ' Finally, Dr. Miller
performed all analytical work'0 2 and wrote the scientific
report for Posilac that was submitted to the FDA. 0 3  Dr.
Miller left Monsanto in 1989 to become a reviewer in the
Antimicrobials and Antiparasitic Branch of the Division of
Toxicology and Environmental Sciences. T10 In this position,
Dr. Miller assisted the FDA to draft an answer to a citizen
petition seeking to halt all sales of milk from cows treated
with rBST. 1°5 In 1992, Dr. Miller became the Branch Chief of
Hormones and Pharmacological Agents in the Division of
Toxicology and Environmental sciences, the branch
responsible for reviewing human safety aspects of Posilac. 106
93. Letter to Congress, supra note 42, at 18.
94. Id.
95. Id.; EPSTEIN, supra note 3, at 260.
96. Letter to Congress, supra note 42, at 18-19.
97. EPSTEIN, supra note 3, at 260; see Letter to Congress, supra note 42, at
18-19.
98. See Letter to Congress, supra note 42, at 20. FDA officials verified Mr.
Taylor's lack of involvement in the approval of Posilac. Id.
99. Interim Guidance, supra note 4; EPSTEIN, supra note 3, at 260; Letter to
Congress, supra note 42, at 20-21.
100. Letter to Congress, supra note 42, at 7-8; see also EPSTEIN, supra note 3,
at 244, 248.
101. Letter to Congress, supra note 42, at 7.
102. Id. at 8.
103. EPSTEIN, supra note 3, at 244, 248.
104. Letter to Congress, supra note 42, at 7-8.
105. Id. at 9-10.
106. Id. at 8-9.
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Basically, the FDA assigned Dr. Miller to the approval of
Monsanto's rBST.10 7
2. Monsanto Infiltrates the System
Former Secretary of Defense Donald Rumsfeld was
president of Monsanto's subsidiary, Searle
Pharmaceuticals. 0 8 Lidia Watrud, former Monsanto biotech
researcher, is currently the senior scientist at the EPA
Environmental Effects Laboratory.1 9 Former Secretary of
Agriculture, Anne Veneman, was on the board of directors for
a Monsanto subsidiary.110  Former Health and Human
Services Secretary, Tommy Thompson, while acting governor
of Wisconsin, used state funds to set up a $317 million dollar
biotech zone for the use of Posilac in Wisconsin"' after
receiving $50,000 in campaign contributions from biotech
companies." 2  Monsanto also contributed to other political
campaigns, including those of Attorney General John
Ashcroft and Richard Pombo, chairman of the Agriculture
Subcommittee on Dairy, Livestock, and Poultry." 3
3. Monsanto Comes Under Investigation
At the request of three Members of Congress, 1 4 the GAO
investigated the conflicts of interested on the part of Michael
Taylor, Dr. Margret Miller, and Dr. Suzanne Sechen." 5
Further, Congress asked the GAO to determine whether "any
FDA employees involved in the approval of Posilac had an
appearance of the loss of impartiality because of a prior
107. See Robert Cohen, The Bully's New Victim,
http://www.Notmilk.com/monsantoland.html (last visited Mar. 23, 2008).
108. Editorial, supra note 91.
109. EPSTEIN, supra note 3, at 248.
110. IDAHO OBSERVER, supra note 91.
111. Id.; see also Rebecca Leighton Katers, The Corporate Federal Takeover,
http'//www.foxriverwatch.com/nrda/nrda-corporatetakeover.html (last visited
Jan. 11, 2007).
112. IDAHO OBSERVER, supra note 91.
113. Id.
114. Letter to Congress, supra note 42, at 1. The requesting members were:
The Honorable George E. Brown, Jr., Chairman, Comm. on Sci., Space and
Tech., H.R.; The Honorable David Obey, H.R.; and The Honorable Bernard
Sanders, H.R. Id. at 1.
115. Letter to Congress, supra note 42, at 1, 3. The FDA hired Dr. Sechen in
1988 as an animal scientist. Id. at 16. Prior to her employment at the FDA, Dr.
Sechen conducted research on investigational rBST formulas at Cornell
University for Monsanto. Id.
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relationship with Monsanto."116 The GAO concluded that
"there were no conflicting financial interests with respect to
the drug's approval or the voluntary milk labeling
guidance."" 7
Despite the GAO's conclusion, foreclosing conflicts of
interest between three former employees of Monsanto and
their role in the FDA, Posilac's approval remains suspect.
Numerous potential conflicts exist that the GAO left
unexamined. Monsanto has been the subject of criminal
investigations for fraud, including falsified studies in its past
endeavors." 8 Monsanto's political influence and poor track
record, at the very least, demonstrate the dubious nature of
Posilac's approval.
D. Labels Become a Battlefield
After Posilac was approved, the FDA declined to mandate
labeling of products originating from cows treated with
rBST." 9 Those dairy farmers not using rBST on their herds
showed their disapproval by indicating on the labels that
their dairy products came from cows not treated with rBST. 2 °
As discussed below, battles ensued between Monsanto and
those dairy farmers who distinguished their milk on labels.'21
116. Id at 1.
117. Id. The GAO based its conclusion on an investigation that consisted of:
reviewing more than 40,000 pages of documents; conducting fifty-four
interviews with current and former FDA and DHHS employees, attorneys,
Monsanto officials, and editors of scientific journals; reviewing the financial
disclosure and conflict-of-interest statements of all CVM employees who played
a significant role in Posilac's approval; and reviewing the relevant ethical
standards. Id.
118. Internal Memorandum of the EPA from William Sanjour, Policy Analyst
to David Bussard, Dir., Characterization and Assessment Div. (July 20, 1994),
available at httpJ/pwp.lincs.net/sanjour/monsanto.htm. In 1990, the EPA Office
of Criminal Investigation recommended "a full field criminal investigation" of
Monsanto for potential criminal violations of three laws: (1) 15 U.S.C. 2615(b),
the Toxic Substances Control Act (TSCA), requiring persons to report any
substantial risk of their products to the EPA and providing criminal penalties
for knowing violations; (2) 18 U.S.C. 371, conspiracy to defraud the United
States; and (3) 18 U.S.C. 1001, making a false statement on a matter within the
jurisdiction of any agency in the United states. Id.
119. Interim Guidance, supra note 4.
120. See infra Part III.D.2-3.
121. See infra Part III.D.2-3.
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1. The Food, Drug, and Cosmetic Act of 1938
The FDA, a federal agency currently organized under the
Department of Health and Human Services, is primarily
responsible for administering the Food Drug & Cosmetic Act
of 1938 (FDCA). 122 As mentioned in the previous section, 123
the FDA did not require farmers to provide labels on milk
that would identify a product as originating from cows
treated with rBST. 124 The FDA made the decision not to
require labeling based on its interpretation of the FDCA and
after a joint meeting of the Veterinary Medicine and Food
Advisory Committees in May 1993.125 At the meeting, the
committees heard testimony from several members of the
medical and scientific communities as well as dairy farmers,
dairy organizations, and farm and agricultural groups. 26
Despite several committee members concluding there were
possible health consequences associated with the use of
rBST, 127 the FDA concluded that there are no significant
differences in milk from rBST treated cows and milk from
untreated cows. 128
The FDCA specifically addresses the issue of food
labeling,'29 but the use of subjective terms has ignited heated
debate over whether the FDA should mandate that
genetically modified foods be labeled. Under the FDCA
section 403(a), 21 U.S.C. section 343(a), a food is misbranded
in violation of the Act if "its labeling is false or misleading in
any particular."13° Section 201(n) of the Act defines the term
"misleading" as it is used in section 403(a):
In determining whether the labeling or advertising is
misleading there shall be taken into account (among other
things) not only representations made or suggested by
122. 21 U.S.C. §§ 301-94 (2006); see FDA, Laws Enforced by the FDA and
Related Statutes,, http://www.fda.gov/opacom/laws/default.htm (last visited Feb.
15, 2008).
123. See supra Part I.
124. See supra Part I.
125. Executive Branch Study, supra note 18.
126. Stauber v. Shalala, 895 F. Supp. 1178, 1186 (W.D. Wis. 1995).
127. Executive Branch Study, supra note 18.
128. Id.; see also Stauber, 895 F. Supp. at 1186 ("[T]he FDA concluded that
there is no significant difference between milk from cows treated with Posilac
and milk from untreated cows.").
129. See The Food, Drug, and Cosmetic Act (FDCA) § 403(a), 21 U.S.C. §
343(a) (2006); FDCA § 201(n), 21 U.S.C. § 321(n).
130. FDCA § 403(a), 21 U.S.C. § 343(a).
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statement, word, design, device, or any combination
thereof, but also the extent to which the labeling or
advertising fails to reveal facts material in light of such
representations or material with respect to consequences
which may result from the use of the article to which the
labeling or advertising relates under the conditions of use
prescribed in the labeling or advertising thereof or under
such conditions of use as are customary or usual. 131
Courts have provided further clarification into the
standards for what is misleading. When considering how a
label may be interpreted by a consumer, courts generally do
not use the objective "reasonable person" standard. Instead,
courts have imputed a lower standard by evaluating the
labels as a consuming public would, which they characterize
as "ignorant," "unthinking," and "credulous."32  All
statements that may mislead or deceive are prohibited; they
are not confined to those claims that omit material
information and include "the use of statements not
technically false or which may be literally true."33
The FDA uses the second part of section 201(n),
regarding "material" facts and consequences, to require
labeling for safety reasons. 3 4 Such warning statements may
be placed on food labels only where there is scientifically-
based evidence of a potential health hazard. 35  Monsanto
submitted scientific reports that disregard possible health
consequences associated with consumption of foods from
rBST-treated cows voiced by members of the advisory
committee. 36 The FDA subsequently concluded no adverse
health consequences would result. 3v  Therefore, the FDA
found it did not have the authority under the FDCA to
131. FDCA § 201(n), 21 U.S.C. § 321(n).
132. See United States v. An Article . . . Consisting of 216 Individually
Cartoned Bottles, More or Less, of an Article Labeled in part: Sudden Change,
etc., Hazel Bishop, Inc., 409 F.2d 734, 740 (2d Cir. 1969); see also Florence Mfg.
Co. v. J.C. Dowd & Co., 178 F. 73, 75 (2d Cir. 1910); United States v. An Article
of Food . . . "Manischewitz . . .Diet Thins", 377 F. Supp. 746, 749 (E.D.
N.Y.1974).
133. United States v. Ninety-Five Barrels (More or Less) Alleged Apple Cider
Vinegar, Douglas Packing Co., 265 U.S. 438, 442-43 (1924).
134. Executive Branch Study, supra note 18.
135. Id.
136. Id.
137. See Interim Guidance, supra note 4; Letter to Congress, supra note 42
at 1-4; Stauber v. Shalala, 895 F. Supp. 1178 (W.D. Wis. 1995).
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require labeling of milk.138
In February 1994, Michael Taylor issued the FDA's
Interim Guidance on the Voluntary Labeling of Milk and Milk
Products from Cows That Have Not Been Treated with
Recombinant Bovine Somatotropin.139 These guidelines warn
of potential violations of section 201(n) and 403(a) of the
FDCA through the use of misleading statements that imply
that milk originating from cows not treated with rBST is
somehow better than or compositionally different than milk
from treated cows. 4 ° The guidelines suggest that to avoid
consumers being misled, any voluntary statements made by
producers or retailers should be followed by further
information such as "no significant difference has been shown
between milk derived from rbST-treated and non-rbST-
treated cows."
141
2. The People Speak Out
The FDA guidelines are intended to function as a
reference for states when interpreting their own statutes.
However, complying with the FDA's suggested terminology
does not automatically protect producers and retailers from
litigation. Nevertheless, milk production traditionally has
been regulated by the states. Therefore, state statutes on the
subject of labeling are controlling because there are currently
no federal laws on the subject to preempt state law. 4 2
In Stauber v. Shalala,143 consumers of dairy products
sought declaratory and injunctive relief pursuant to the
FDCA. Plaintiffs alleged, among other things, that the FDA
should require mandatory labeling of milk from treated cows
in order to comply with 21 U.S.C. section 343(a)(1) and
section 321(n).'" Plaintiffs argued that differences exist
between milk from treated and untreated cows and that these
138. Executive Branch Study, supra note 18.
139. Interim Guidance, supra note 4.
140. Id. The guidelines suggest that milk labeled as "rBST free" may imply a
compositional difference that would be misleading in violation of the Act and
that the more appropriate phrase is, "from cows not treated with rBST."
However, even this preferred phrasing "has the potential to be misunderstood
by consumers ... such statements could be misleading." Id.
141. Id.
142. Id.; see also U.S. CONST. art. I, § 8, cl. 3.
143. Stauber v. Shalala, 895 F. Supp. 1178 (W.D. Wis. 1995).
144. Id. at 1192.
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differences are "material facts" under the Act, which require
labeling.14 In addition, plaintiffs argued that consumer
demand for labeling is also a "material fact" that requires
labeling.146
Courts give great deference to the decisions made by the
FDA as a federal agency. Federal court review is limited and
employs the highly deferential "arbitrary and capricious"
standard of review.147 This means that even if a court were to
disagree with the FDA's decision, as long as there is a
discernable rational basis for the FDA's action, the court will
uphold it as valid.14
As a result of this great deference, the Wisconsin District
Court in Stauber subsequently upheld the FDA's decision to
decline mandatory labeling because it was based on scientific
evidence in Monsanto's reports, which found that rbST posed
no significant risk to consumers, and that there was no
significant difference in milk from treated and untreated
cows. 49  The District Court refused to admit evidence
submitted by the plaintiffs that demonstrated negative
human health consequences caused by rBST.150 Chief Judge
Crabb, writing for the majority of the court stated, "plaintiffs
cannot ask this court to rely on opinions within the medical
community regarding health risks posed by rBST without
first establishing that those opinions were presented to the
FDA before it granted approval of Posilac."' 5 ' Despite the fact
that the FDA approves drugs with sometimes deadly side
effects that are not discovered until after approval,152 Judge
Crabb, acknowledging that no long-term studies were
145. Id. at 1193.
146. Id.
147. Id. at 1189.
148. Id.
149. Stauber v. Shalala, 895 F. Supp. 1178, 1183 (W.D. Wis. 1995).
150. Id. at 1190.
151. Id. (emphasis added).
152. See Dissertation, supra note 15. Some examples include Vioxx, Rezulin
and Aspartame. Vioxx remained on the market for four years and was the cause
of over 10,000 deaths; Rezulin was on the market for three years despite
evidence of its deadly liver toxicity. Dissertation, supra note 15. Additionally
Aspartame, which is still currently available in over 7,000 products, has been
attributed to over ninety toxic adverse reactions including Alzheimer's disease
and death. Betty Martini & Don Harkins, The Legacy of Donald Rumsfeld:
Diseases Bearing His Name, Millions of People Sick and Dying From Them -
And Diane Fleming, THE IDAHO OBSERVER, Nov. 2006, available at
http://proliberty.com/observer/20061115.htm.
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conducted, would not accept scientific evidence of potential
harm to humans if such studies were performed subsequent
to the FDA's approval.'53 The District Court's refusal to
admit evidence simply because it was concluded after
approval is illogical. Under the District Court's view no
challenge to rBST could possibly be successful since the great
deference afforded to the FDA's decision would require the
FDA to conduct independent investigation. Despite mounting
evidence of serious health risks associated with rBST, it will
remain on the market.
3. Monsanto and Dairy Manufacturers Challenge
Labels
Dairy manufacturers challenged the constitutionality of a
Vermont statute that required mandatory labeling of milk
derived from treated cows in International Dairy Foods Ass'n
v. Amestoy."' The Second Circuit Court of Appeals struck
down a statute that required all milk and milk products
originating from rBST-treated cows to disclose that
information on the label or packaging' 5 on the grounds that
the statute compelled speech in violation of the manufacturer
plaintiffs' First Amendment rights. 56  The court reasoned
that Vermont could not justify the statute on consumers'
curiosity alone. "Some indication that this information bears
on a reasonable concern for human health or safety or some
other sufficiently substantial governmental concern" is
needed to force manufacturers to involuntarily disclose the
information. 57
Displeased by any statement that identified a product as
coming from untreated cows, Monsanto sent out 2,000 letters
threatening to sue manufacturers 5 8 if they made statements
similar to those of manufacturers, retailers, states, and
dairies whose voluntary labeling methods Monsanto was
challenging in the courts.'59  One such label, used by
153. Stauber, 895 F. Supp. at 1192.
154. Int'l Dairy Foods Ass'n v. Amestoy, 92 F.3d 67, 69 (2d Cir. 1996).
155. Id. at 69.
156. Id.
157. Id. at 74.
158. Thornley, supra note "d, at 799.
159. Id. Monsanto challenged the voluntary labeling methods of Oakhurst
Dairies, Swiss Valley Farms, Pure Milk and Ice Cream Company, and the State
of Maine, among others. Id.
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Oakhurst Dairy read: "'Our Farmers' Pledge: No Artificial
Growth Hormones."6 °  Monsanto filed suit seeking an
injunction to prohibit the dairy from using the statement.
The parties settled the suit out of court, and Oakhurst agreed
to amend its pledge to include the word "used," as well as
adding the phrase: "FDA states: No significant difference in
milk from cows treated with artificial growth hormones."161
Monsanto's attempt to suppress consumer knowledge of
rBST has gone beyond dairy producers and manufacturers.
When Fox Television investigative reporters composed a story
that revealed the adverse health effects linked to rBST,
Monsanto responded with a letter to the head of Fox News
threatening litigation if the story aired. 62 The story was then
rewritten several times."6 3 Monsanto required the removal of
all references to the word cancer,'6 and although European
officials had banned rBST because of health concerns, 65 the
story was to report that no such concerns existed. 166
Ultimately, the story never aired and the two reporters were
subsequently fired for refusing to report lies. 67  Although
Monsanto and the courts currently hold that consumers have
no right to know the milk they drink comes from cows treated
with rBST, all hope is not lost. The Federal Government is
the solution.
III. IDENTIFICATION OF THE PROBLEM
Recombinant DNA techniques are relatively new and
experimental. Studies conducted by members of the scientific
160. Press Release, supra note 7.
161. Sharon Kiley Mack, Oakhurst Reaches Settlement on Label - Dairy,
Chemical Company Avoid Trial, BANGOR DAILY NEWS, Dec. 25, 2003, at Al.
162. Jane Akre, Modern Media's Environmental Coverage: What We Don't
Know Can Hurt Us, 33 B.C. ENVTL. AFF. L. REv. 551, 551 (2006).
163. Id. at 554.
164. THE CORPORATION (A Film by Mark Achbar, Jennifer Abbott & Joel
Bakan 2003).
165. Akre, supra note 162, at 554.
166. Id.
167. Id. Jane Akre, one of the Fox reporters fired for refusing to report the
modified rBST story, filed a whistleblower lawsuit against the news
organization alleging that Fox could not report false news and was in violation
of the Federal Communications Commission's prohibition against news
distortion. Although the trial court found for Akre, Fox appealed and the
appellate court overturned the verdict because lying to the public is not in
violation of any law, rule or regulation. Id. at 554-56; see also New World
Commc'ns of Tampa, Inc. v. Akre, 866 So. 2d 1231 (Fla. Dist. Ct. App. 2003).
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community independent of Monsanto's research team
contradict the corporation's conclusion that rBST is safe. A
two-week study of toxicity performed on lab rats is
inadequate to evaluate the possible health and safety
consequences from prolonged exposure to rBST. The current
labeling structure is misleading in that it implies there is no
difference between milk from cows treated with rBST and
untreated cows, when, in fact there is. Consumers have a
strong desire to know whether the milk they purchase comes
from treated cows 168 and they should be entitled to this
information via labels.
IV. ANALYSIS
There are three possible solutions to the problem of
mandatory labeling of milk products that originate from cows
treated with rBST. These solutions are derived from three
separate sources of power: the courts, the FDA, and the
Federal Government. First, the courts can reevaluate
whether there is a sufficient state interest to compel speech
without violating the First Amendment rights of dairy
producers and manufacturers. Second, the FDA may require
labeling of rBST products if it finds that there is sufficient
evidence that harm may result from consumption of these
products. Finally, the Federal Government may mandate
labels of rBST products via the Commerce Clause.
A. States' Interest Sufficient to Compel Speech
First, the logic of the Second Circuit in International
Dairy should be reevaluated. However, this is not likely
because every rBST label Monsanto has challenged so far has
settled out of court. The high costs of litigation discourage
many dairy producers from fighting the good fight, and allow
Monsanto to retain control over what is printed on the
packaging. Fearful of a costly battle, many states and
producers adhere to the FDA's suggested guidelines. 169 Still,
if International Dairy were litigated today, a court would
likely follow Judge Leval's dissent and uphold the state's
compulsory labeling scheme as a valid exercise of the state's
168. Int'l Dairy Foods Ass'n v. Amestoy, 92 F.3d 67, 75 (2d Cir. 1996);
Stauber v. Shalala, 895 F. Supp. 1178, 1183 (W.D. Wis. 1995).
169. ME. REV. STAT. ANN. tit. 7, § 2901-A (2005).
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police powers. 7 °
The First Amendment protects speech from government
regulation.17' The largest exception to this general grant of
freedom is known as the "commercial speech doctrine." The
United States Supreme Court defined commercial speech as
speech that merely proposes a commercial transaction. 172
While non-commercial speech receives complete First
Amendment protection, 7 3  commercial speech receives a
significantly lesser degree. 174  The Court reasoned that full
protection of commercial speech is not required to ensure that
the flow of truthful and legitimate commercial information is
unimpaired, 175 because of the "common sense" differences that
exist between commercial and non commercial speech.176
170. Int'l Dairy, 92 F.3d at 74 (Leval, J., dissenting) ("Vermont's regulation
requiring disclosure of use of rBST in milk production was based on substantial
state interests, including worries about rBST's impact on human and cow
health, fears for the survival of small dairy farms, and concerns about the
manipulation of nature through biotechnology. The objective of the plaintiff
milk producers is to conceal their use of rBST from consumers."). In the
dissenting opinion, Judge Leval points out the Majority's disregard of evidence
that shows Vermont's true interests and the district court's findings that
recognized those interests. Id. at 76. Leval opines that the "interests of the
citizenry that led to the passage of the law include health and safety concerns,
among others." Id. The concerns Vermonters voiced were based on their beliefs
that: (1) the use of genetically-engineered hormones is unnatural; (2) small
dairy farmers will be hurt by the use of rBST because the increased milk
production will result in lower prices; (3) the use of rBST is harmful to cows and
potentially harmful to humans; and (4) there is a lack of knowledge regarding
long term effects associated with rBST. Id. at 75-76.
171. U.S. CONST. amend. I.
172. Va. State Bd. Pharmacy v. Va. Citizens Consumer Council, Inc., 425
U.S. 748, 762 (1975) (citing Pittsburgh Press Co. v. Pittsburgh Comm'n on
Human Relations, 413 U.S. 376, 385 (1976)) ("[Commercial speech] does no
more than propose a commercial transaction."); Cent. Hudson Gas & Elec. Corp.
v. Pub. Serv. Comm'n of N.Y., 447 U.S. 557, 561 (1980) (defining commercial
speech as "expression related solely to the economic interests of the speaker and
its audience").
173. First Amendment rights are only affected through private claims of
defamation, libel or slander. See e.g., Siegert v. Gilley, 500 U.S. 226 (1991);
R.A.V. v. St. Paul, 505 U.S. 377 (1992); Wolston v. Reader's Digest Ass'n, 443
U.S. 157 (1979).
174. Va. State Bd. Pharmacy, 425 U.S. 748. The longstanding belief that
commercial speech is less valuable than other types of speech was solidified
with the Supreme Court's decision in Central Hudson, when the court held that
commercial speech is categorically worthy of less protection. Cent. Hudson, 447
U.S. at 561.
175. Va. State Bd. Pharmacy, 425 U.S. at 771 ("Untruthful speech,
commercial or otherwise, has never been protected for its own sake.").
176. Id. (stating that commercial speech is more "objective" since it is easily
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In Central Hudson Gas & Electric Corp. v. Public Service
Commission of New York, the United States Supreme Court
established the test for governmental regulation of speech. 177
Under the Central Hudson test, if commercial speech is false,
deceptive, or misleading, states are not restrained in
preventing dissemination. 17  However, if commercial speech
is truthful,'79 states cannot prevent dissemination unless
there is a substantial governmental interest, the means
chosen directly advances that interest, and no less
burdensome alternatives exist.18 0
In International Dairy, the Second Circuit Court of
Appeals held that Vermont's mandatory labeling requirement
was invalid as a violation of the plaintiffs First Amendment
rights because it found that the interest asserted by Vermont
was not substantial.' The majority suggested that if health
or safety concerns had been the motivating force for
instituting the regulations rather than mere "consumer
interest and the public's right to know," Vermont's interest
would have qualified as substantial. 8 2  As the dissent
correctly stated, the majority opinion "simply disregards the
evidence of Vermont's true interests and the district court's
findings recognizing those interests."8 3
Vermont did not advance any scientific evidence
contradicting the FDA's claims of safety. Instead, it stated
that consumers believed that the use of rBST causes harm to
cows and is potentially harmful to humans. l '4 While, as
Judge Leval's dissenting opinion stated, consumer's
legitimate belief of potential harm should be a substantial
state interest, today, there is more than consumer's fear of
potential harm. There is scientific evidence. Increased
cancer risks from higher IGF-1 levels and risks of exposure to
verifiable and that commercial speech is unlikely to be chilled because it is
driven by profits).
177. Cent. Hudson, 447 U.S. at 557.
178. Id. at 566; Zauderer v. Office of Disciplinary Counsel of Supreme Court
of Ohio, 471 U.S. 626, 638 (1985).
179. "Truthful" in this context means that the commercial speech is not false,
deceptive or misleading.
180. Cent. Hudson, 447 U.S. at 566; see also Int'l Dairy Foods Ass'n v.
Amestoy, 92 F.3d 67, 77 (2d Cir. 1996).
181. Int'l Dairy, 92 F.3d at 73.
182. Id. at 72-73.
183. Id. at 76.
184. Id.
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antibiotics due to increased incidents of mastitis have been
sufficiently demonstrated to support government interest in
the health and safety of its citizens."' 5
To have a permissible statute for regulating commercial
speech, the means chosen must also directly advance the
substantial state interest in a way "no more intrusive than
necessary to accomplish its goal."'8 6 By compelling those who
use rBGH to disclose that information to purchasers, the
state is helping consumers protect themselves against these
increased health risks. Although some labeling strategies
will undoubtedly result in increased costs to the dairy
producers and manufacturers, methods such as Vermont's
"blue sticker"8 7 would be slight and likely would be passed
onto the consumer by increasing the cost a few cents per
gallon, a small price to pay for what most consumers would
consider valuable knowledge.
B. FDA's Narrow Construction of Sections 343(a) and
201(n)-Misleading and Materiality
Monsanto has used sections 343(a) and 201(n) of the
FDCA as the basis for its claims against those who choose to
identify their milk products as "rBGH free." Monsanto
vehemently insists that the display of two simple words,
"rBGH free," that are, in fact, pure unadulterated truth, on
milk packaging is an attempt by those whose cows are
untreated to "mislead" and "deceive" consumers into believing
that milk with these labels is safer or healthier. 8 Monsanto
argues that labels should be required to "provide consumers
with the accurate scientific context about milk from cows
185. See EPSTEIN, supra note 3; TOWNSEND, supra note 44; Toronto, supra
note 51.
186. Cent. Hudson Gas & Elec. Corp. v. Public Serv. Comm'n of N.Y., 447
U.S. 557, 566 (1980).
187. See Int'l Dairy, 92 F.3d at 70. Manufacturers who used rBST had to
comply with one of four options to reveal that information. One such option was
to post a sign in stores selling dairy products that stated: "The products in this
case that contain or may contain milk from rBST-treated cows either (1) state
on the package that rBST has been or may have been used, or (2) are identified
by a blue shelf label [blue rectangle] or (3) a blue sticker on the package [blue
dot]. The [US FDA] has determined that there is no significant difference
between milk from treated and untreated cows. It is the law of Vermont that
products made from the milk of rBST-treated cows be labeled to help consumers
make informed shopping decisions." Id.
188. Press Release, supra note 7.
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supplemented with rBST so that consumers can make an
informed choice."" 9 The problem with Monsanto's position is
that it considers only the scientific reports by its people,
which indicate the use of rBST as safe for human
consumption. Monsanto brushes aside the contradictory
scientific evidence compiled by those impartial researchers
outside of Monsanto's reach, and even results of some within
its grasp, 190  as unnecessary to consumers making an
"informed" decision.
Through bully tactics, Monsanto has made inclusion of
the statement, "there is no significant difference between
milk from cows treated with rBST and milk from untreated
cows," an unspoken law.191 Employing the "ignorant,
unthinking, credulous" consumer standard, this disclaimer is
deceptive and misleading under section 201(n).192 Consumers
are likely to infer from this statement that adequate long-
term human toxicity testing of rBST has been performed,
when it has not. The FDA's conclusions as to the safety of a
drug are not a guarantee. 93 Consumers put their trust in the
hands of the FDA, unaware of the numerous drugs that
passed FDA standards only to cause related adverse side-
effects, such as heart-attack, sexual dysfunction, and even
death post-approval.'94
In Stauber, the plaintiffs alleged two bases of support for
their assertion that the FDA should require mandatory
labeling of milk from cows treated with rBGH.' 95 First, they
claimed that organoleptica1 96 differences exist between milk
189. Id.
190. TOWNSEND, supra note 44. Dr. Burroughs, while employed for the FDA
spoke, out against safety concerns from lack of research as did other members of
the scientific community before the FDA in the joint committee hearing on the
labeling of rBST. Id.; Stauber v. Shalala, 895 F. Supp. 1178, 1186 (W.D. Wis.
1995).
191. See supra Part II.D.3.
192. See FDCA § 201(n), 21 U.S.C. § 321(n) (2006).
193. Int'l Diary Foods v. Amestoy, 92 F.3d 67, 77 (2d Cir. 1996).
194. See Don Harkins, Power Politics Trumped Public Health in Aspartame
Approval Process, IDAHO OBSERVER, June 2004, available at
http://www.proliberty.conobserver/20040604.htm. After the FDA approved
aspartame, a synthetic sweetener currently used in over 7,000 products
nationwide, it published a list of 92 symptoms of aspartame poisoning
including, "asthma, brain cancer, sexual dysfunction, irritability, seizures,
vision problems, weight gain, chronic fatigue and death." Id.
195. Stauber, 895 F. Supp. at 1193.
196. Organoleptical differences are those capable of being detected by the
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from treated cows and milk from untreated cows, which are
"material facts" under section 201(n). 197 Further, plaintiffs
argued that high consumer demand for the right to know is
also a "material" fact. 9 ' The Wisconsin district court rejected
both contentions. 99
The FDA considers differences in performance
characteristics and organoleptic differences as material facts
under section 201(n), which must be disclosed to prevent
misbranding under section 403(a).200 Since human sense
organs cannot detect difference between the two milks, the
district court was correct in stating there are no organoleptic
differences between the two milks; thus, under current
interpretation of the FDCA, the FDA cannot mandate
labeling under this premise. 201 There are also no differences
in the performance characteristics 2 2 of milk that comes from
treated and untreated cows that would permit the FDA to
require labeling. However, the FDA neglects major
differences by refusing to consider the process of genetic
engineering, which itself makes the two dissimilar, or the
three percent difference in composition that the FDA now
admits exists between the two milks, as material.2 3
The plaintiffs' second argument that labeling should be
mandated because consumer demand is a material fact also
fails to establish a sufficient legal basis. Nowhere in the
FDCA is authorization given to require action due to
consumer demand. 24 As the court in Stauber stated, if "the
product does not differ in any significant way from what it
purports to be, then it would be misbranding to label the
product as different, even if consumers perceive the product
as different."2"' The plaintiffs in Stauber did not argue health
and safety reasons as justification for labeling. Even if they
human senses. THE MIRIAM-WEBSTER DICTIONARY (llth ed. 2003)
197. Stauber, 895 F. Supp. at 1193.
198. Id.
199. Id.
200. Id.
201. Id.
202. Id. The FDA considers performance characteristics to be: physical
properties (color, consistency), flavor characteristics, functional properties, and
shelf life. Id.
203. EPSTEIN, supra note 3, at 2.
204. See FDCA, 21 U.S.C. §§ 301-394 (2006).
205. Stauber, 895 F. Supp. at 1193.
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had, the court would have refused the evidence.2"6 Since
technically increased levels of IGF-1 are not detectable by
humans during consumption or inspection, the plaintiffs
incorrectly focused on organoleptic differences when they
should have presented safety concerns as justification under
the "material fact" portion of section 201(n).207 Although the
court in Stauber refused to consider such contrary findings,208
with such mounting proof of harm and unsettling consumer
demand, a court today would likely permit such evidence.
Section 201(n) authorizes the FDA to require labeling to
reveal facts that are material "with respect to consequences
which may result from the use of the article."20 9  There is
sufficient scientific evidence in existence today about the
harm associated with the ingestion of milk from treated cows
to satisfy section 201's "may result" standard. So far, the FDA
has ignored findings by members of the scientific and medical
communities that show the harm associated with rBST.21° If
the FDA acknowledged studies performed by those other than
Monsanto's people, it would find it has authority under
section 201(n) to mandate labeling of products from rBST-
treated cows.
C. Federal Regulation via the Commerce Clause
If the FDA continues to turn a blind eye to scientific
evidence that shows risks of significant harm associated with
rBST, and maintains the position that it lacks authority
under the FDCA to require labeling, then Congress by virtue
of the Commerce Clause can explicitly mandate labeling by
amending the FDCA or enacting other legislation. Currently,
states are able to regulate labels intrastate because no federal
laws have preempted such state statutes through complete
occupation of the field. 211 Although the FDCA authorizes the
FDA to require labeling, regulating milk is traditionally the
role of the states, creating a presumption that federal
206. Id. at 1192-93.
207. FDCA § 201(n); 21 U.S.C. § 321(n).
208. Stauber, 895 F. Supp. at 1190.
209. FDCA § 201(n); 21 U.S.C. § 321(n).
210. Letter to the Editor, supra note 12.
211. See generally Chi. and N.W. Transp. Co. v. Kalo Brick & Tile Co., 450
U.S. 311 (1981); Merrill Lynch, Pierce, Fenner & Smith, Inc. v. Ware, 414 U.S.
117 (1973).
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legislation was not meant to preempt state law.2 12
However, Congress has the authority to limit the states'
control by enacting legislation that requires labeling of all
rBST-treated milk and milk products that travel in interstate
commerce 213 or that substantially affect interstate
commerce. 214 Article I, section 8, clause 3 of the United States
Constitution, the "Commerce Clause," authorizes the federal
government to regulate persons and things in interstate
commerce, as well as those activities that have a substantial
effect on interstate commerce.215 Congress has the authority
to regulate the labeling of milk and milk products that cross
state boarders under the commerce power. Under the rule
established in NLRB v. Jones & Laughlin Steel Corp.,216
Congress is able to regulate the labeling practices of milk sold
intrastate by producers who also sell their milk interstate.2 7
The parameters of activities such as milk production,
which traditionally have been regulated by the states and are
conducted wholly intrastate, are still unclear and may be
outside the scope of the commerce power. Nevertheless, the
aggregation principle established in Wickard v. Filburn
218
arguably allows regulation of labeling even on wholly
intrastate milk producers. The aggregation principle applies
only to economic activities, 2 9 and the commercial sale of milk
is an economic activity. If intrastate producers are not
subject to the same mandatory labeling scheme as interstate
212. Interim Guidance, supra note 4.
213. U.S. v. Darby, 312 U.S. 100 (1941).
214. Wickard v. Filburn, 317 U.S. 111 (1942).
215. U.S. CONST. art. I, § 8, cl. 3; Wickard v. Filburn, 317 U.S. 111 (1942);
United States v. Lopez, 514 U.S. 549 (1995); Perez v. United States, 402 U.S.
146 (1971); NLRB v. Jones & Laughlin Steel Crop., 301 U.S. 1, 37 (1937).
216. NLRB, 301 U.S. 1.
217. See id. The Court held the federal government has the power to regulate
local employment practices in companies whose business effects interstate
commerce. Id.
218. Wickard, 317 U.S. 111. The defendant farmer was penalized for
growing wheat in excess of his allotment under the federal Agricultural Act.
The Supreme Court found the purpose of the Act was to restrict the supply of
wheat in order to maintain prices, and although the amount grown by the
defendant for consumption on his farm was trivial, when taken in the aggregate
it could have an effect on interstate prices. Id.; see also Gonzales v. Raich, 545
U.S. 1 (2005); Perez v. United States, 402 U.S. 146 (1971).
219. United States v. Morrison, 529 U.S. 598 (2000) (holding Congress cannot
use the Commerce Clause to regulate a local non-economic activity, even if the
national aggregate of the activity substantially affects interstate commerce).
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producers, this would have a substantial effect on the price of
milk nationwide.
Milk derived from rBST-treated cows sells at an average
of forty cents less per gallon than milk labeled "rBGH-free."22 °
If intrastate producers were not required to label milk
produced from cows treated with rBST, they would be able to
charge a higher price than rBST-treated milk from out-of-
state producers packaged with identifying labels. Consumers
might be misled to believe that an unlabeled carton of milk
comes from cows not treated with rBST, since most producers
would not label their product as coming from treated cows if
they were not required to do so. Such deception in the
marketplace would have a substantial effect on the price of
milk nationwide. Therefore, because of the aggregate effect on
milk prices nationwide, and in the interest of uniformity,
Congress should regulate the labeling of wholly intrastate
milk production under the commerce power.
V. PROPOSAL
There are three possible paths that all lead to the
solution to the rBST-treated labeling issue. First, the federal
government can act pursuant to the Commerce Clause to
create a law that requires all producers of milk and milk
products derived from rBST-treated cows to disclose this
information on the product packaging or label. Second, under
existing law, the FDA can require a compulsory labeling
scheme in the interest of the health and safety of United
States citizens. Finally, the Federal Government could allow
producers and manufacturers of milk not treated with rBST
to state possible health risks associated with rBST to
consumers on the milk packaging or label.
A. Federal Government Should Regulate
The most effective option is for the federal government to
enact legislation requiring all milk and milk products derived
from rBST-treated cows be labeled as such. In addition, such
"qualifying" statements as "the FDA finds no significant
difference" should be banned as misleading.
220. See Bruce Mohl, Stores Hike Prices on Milk Free of Synthetic Hormones,
THE BOSTON GLOBE, Oct. 10, 2006, at El.
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The FDCA was enacted for the protection of consumers.
Thus, the FDA has an obligation to uphold this duty and act
in the best interests of the health and safety of the general
public. Corporate influence has penetrated today's society,
and numerous conflicts of interest bind Monsanto to the
FDA.222 There is something seriously wrong with the FDA
when researchers present glaring scientific evidence, warning
of the possible risks associated with the continued use of
rBST, and it chooses to ignore the facts. Monsanto's lack of
credibility has been shown time and time again.223 The
people of the United States need protection. Congress is in
the best position to provide effective defense.
B. FDA Can Require Mandatory Labeling Under Section 201
The second, and less likely, alternative is for the FDA to
acknowledge that it has authority under the FDCA to require
producers and manufacturers of cows treated with rBST to
identify this on their product label or packaging. The FDA
need only look to evidence other than that supplied by studies
funded and controlled by Monsanto to see that there are
serious health and safety concerns at issue. Under section
201(n), health risks to consumers such as increased risk of
cancer, allergic reactions, and increased resistance to
antibiotics qualify as "material with respect to consequences
which may result from the use of the article."224 If the FDA
considered such health risks to be a scientifically proven
possibility, it would have authority under the FDCA to
require labeling of rBST-treated products. If the FDA
believed such health and safety issues "may result," its
failure to require disclosure of the use of rBST would be
"misbranding" in violation of section 343(a).
C. Labels Should Reveal Contradictory Studies
The third option is to permit dairy manufacturers and
producers who do not use rBST to state findings of adverse
health effects on consumers or, at least, lack of long-term
studies conducted by the FDA. The following are two
221. Stauber v. Shalala, 895 F. Supp. 1178, 1187 (W.D. Wis. 1995).
222. See EPSTEIN, supra note 3, at 260; Cohen, supra note 107.
223. See Organic Consumers Ass'n, Millions Against Monsanto,
httpJ/www.organicconsumers.org/monlink.cfm (last visited Jan. 15, 2007).
224. FDCA § 201(n); 21 U.S.C. § 321 (2006) (emphasis added).
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examples of statements that are truthful and should be
allowed:
1) "From cows not treated with rBST. The FDA has
concluded that no significant difference in milk from rBST
treated cows and milk from untreated cows exists. No
long term studies on the effect of rBST milk on humans
have been conducted."
2) "From cows not treated with rBST. The FDA has
concluded that no significant difference in milk from rBST
treated cows and milk from untreated cows exists. Milk
from cows treated with rBST may contain increased levels
of IGF-1. Independent scientific research has shown a link
between increased IGF-1 levels and cancer."
Using labels that include facts other than those
permitted by the FDA, gives consumers greater decision-
making power. Although Monsanto will surely claim such
labels are misleading and bring charges against those who
choose to place such statements on their packaging, a judge
could find against Monsanto. If a court accepted scientific
findings other than those contained in Monsanto's reports,
proponents of such labels would have sufficient scientific
evidence to support the above statements. If backed by
evidence, the above statements could not be considered
misleading in violation of section 343.
VI. CONCLUSION
The arrival of genetic engineering was greeted with
mixed reactions. While some farmers and producers benefit
by the increased product yield and lower production costs,
consumers remain wary and demand to know the synthetic
processes by which their foods are made.225 Despite reports
by independent scientists and researchers that demonstrate
negative health consequences,226 the FDA has not yet
acknowledged the dangers related to human consumption of
milk and milk products from rBST-treated cows.
The FDA has the authority under sections 403(a) and
201(n) of the FDCA to order all rBST products provide full
225. Dan Voelpel, Cows Go Natural to Make Milk for Wilcox Farms, THE
NEWS TRIBUNE (Tacoma, Wash.), July 12, 2006.
226. See supra Part II.B.1-2.
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disclosure on their labels.227 Although the court in Stauber
held that consumer demand to know is insufficient to require
labeling, the FDA has required labels for non-health related
issues that are important to consumers such as "dolphin safe"
tuna2 I and farm raised salmon.229  The FDA could require
labeling, but chooses not to.
The FDA's reluctance to appease consumers may be
attributed to corporate influence and the fact that powerful
corporations such as Monsanto, which pay the FDA's
salaries,23 ° speak in a louder voice than the average
consumer. After denying consumers the right to know for over
a decade, it is unlikely that the FDA will alter its
interpretation of the FDCA and require labeling in the near
future. Therefore, the burden must fall on Congress to
protect consumers by enacting a new law that requires
products derived from rBST-treated cows to bear identifying
labels.
227. See supra Part VI.B.
228. 16 U.S.C. § 1385 (1999).
229. 68 Fed. Reg. 61944 (proposed Oct. 30, 2003). Effective April 4, 2005, the
USDA requires mandatory labeling of fish and shellfish products for country of
origin and method of production (i.e., wild or farm-raised). Id.
230. Dissertation, supra note 15.
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